NYXH earnings call for the period ending June 30, 2022.
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results DREAM enrollment complete, 12-month clinical data...
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test Mont-Saint-Guibert, Belgium – August 2, 2022,...
Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET –...
Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Mont-Saint-Guibert, Belgium – July 19, 2022, 10:30pm CET /...
Nyxoah Announces CE Mark Approval for Genio® 2.1 The next generation external activation chip leverages Nyxoah’s scalable platform to continuously...
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse...
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2022, 10:30 pm CET / 4:30 pm...
Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Mont-Saint-Guibert, Belgium – June 7, 2022 4:30pm ET /...
FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and...